Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acne Vulgaris Participants eligible for enrollment in the study must meet all the following 1. Male and females age 18 or older 2. Clinical diagnosis of mild to moderate facial acne vulgaris defined as: 1. ≥5 inflammatory lesions, and; 2. ≥10 non-inflammatory lesions, and; 3. IGA 2-3 3. Willing to refrain from using any treatments, other than the investigational product, for acne present on the face. This includes the use of antibiotics for the treatment of acne. Topical acne treatments that do not have significant or measurable systemic absorption (e.g., benzoyl peroxide, salicylic acid) are allowed for treatment of non-facial acne. 4. Willing and able to provide informed consent and to comply with the study protocol  Pregnant and/or lactating females 2. Continuous or planned use of tanning booths or excessive sun exposure, in the opinion of the Investigator. 3. Active cystic acne or acne conglobata, acne fulminans, and secondary acne 4. Two or more active nodular lesions 5. Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid, or topical probiotics including commercially available product AO+Mist on the face within 7 days prior to baseline. 6. Treatment with systemic corticosteroids within 28 days prior to baseline. 7. Treatment with systemic antibiotics or systemic anti-acne drugs within 7 days prior to baseline. 8. Prescription topical retinoid use on the face within 7 days of baseline (e.g., tretinoin, tazarotene, adapalene). 9. Commencement of new hormonal therapy or dose change to hormonal therapy within 90 days prior to baseline. Dose and frequency of use of any hormonal therapy started more than 90 days prior to baseline must remain unchanged throughout the study. Hormonal therapies but are not limited to, estrogenic and progestational agents such as birth control pills. 10. Use of androgen receptor blockers (such as spironolactone or flutamide) in the 7 days prior to randomization. 11. Oral retinoid use (e.g., isotretinoin) within 180 days prior to baseline or vitamin A supplements greater than 10,000 units/day within 180 days of baseline. 12. Cosmetic facial procedures (chemical or laser peel, microdermabrasion, etc.) within the 28 days of the first dose or during the study. 13. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation. 14. Any condition that the study Investigator feels would indicate that participation would not be in the best interest of the participant. 15. The participant has been previously randomized in this study. 16. The participant has received an investigational product within 30 days or 5 half-lives, whichever is longer prior to randomization